A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity
Novo Nordisk A/S
Summary
This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance using a computer program, so neither participants nor study staff will know which treatment is given. The study will last for about one year.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Male or female (sex at birth) * Age 18 years or above at the time of signing the informing consent. * Body Mass Index (BMI) is greater than or equal to (\>= ) 30.0 kilograms per square metre (kg/m\^2) or BMI \>= 27.0 kg/m\^2 with the presence of at least one obesity-related complication including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. Exclusion Criteria: * Glycosylated haemoglobin (HbA1c) \>= 6.5 % (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1…
Interventions
- DrugCagrisema
Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously using device 1 or device 2.
- DrugPlacebo CagriSema
Placebo matched to Cagrilintide and Placebo matched to Semaglutide will be administered subcutaneously using device 1 or device 2.
Locations (116)
- Uni of Alabama at BirminghamBirmingham, Alabama
- Cahaba ResearchPelham, Alabama
- Advanced Investigative Medicine, Inc.Hawthorne, California
- Southern Cal Clinical ResearchSanta Ana, California
- Encompass Clinical Research_Spring ValleySpring Valley, California
- Chase Medical Research LLCWaterbury, Connecticut